Physician profile
Karen L Carter
NPI 1255441994
$7,607.24
in general payments reported to CMS, 2019-2025
30 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 83% of Neurodevelopmental Disabilities (Pediatrics) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $355 · 2021: $1,473 · 2022: $1,010 · 2023: $1,381 · 2024: $1,766 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,615.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $1,405.37 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $1,356.91 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $1,007.64 | 2019-2024 | Jornay Pm |
| Ucb, INC. | $797.79 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Corium, LLC | $451.08 | 2021-2025 | Azstarys |
| Tris Pharma INC | $441.84 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Acadia Pharmaceuticals INC | $407.12 | 2024-2025 | Daybue |
| Pfizer INC. | $224.47 | 2019-2022 | |
| Baxter Healthcare | $211.37 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $207.29 | 2024-2025 | |
| Aquestive Therapeutics, INC. | $175.03 | 2019-2022 | |
| Neos Therapeutics, Lp | $154.26 | 2020-2021 | |
| Greenwich Biosciences, INC. | $124.98 | 2021 | |
| Adlon Therapeutics L.P. | $100.90 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.12 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $84.18 | 2019-2023 | Smartvest |
| Advanced Respiratory, INC | $81.73 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $56.27 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $29.32 | 2025 | Neffy |
| Biogen, INC. | $25.08 | 2024 | Spinraza |
| Soleno Therapeutics, INC. | $24.39 | 2025 | Vykat Xr |
| Owp Pharmaceuticals, INC. | $24.11 | 2022 | |
| Philips North America LLC | $20.18 | 2025 | Vest Therapy Und |
| Uswm, LLC | $20.00 | 2021 | |
| Novo Nordisk INC | $17.70 | 2023 | Saxenda, Wegovy |
| Metacel Pharmaceuticals LLC | $15.25 | 2025 | Ozobax |
| Amneal Pharmaceuticals LLC | $14.24 | 2023 | Lyvispah |
| Saol Therapeutics INC. | $13.60 | 2019 | |
| Zogenix INC. | $12.54 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.